Boudewijn Kruithof

Dr. Boudewijn Kruithof

Leiden University Medical Center (LUMC), The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
SDSjoerd N. Duim
Sjoerd N. Duim
KKKondababu Kurakula
Kondababu Kurakula
MGMarie-José Goumans
Marie-José Goumans
BKBoudewijn Kruithof
Boudewijn Kruithof

1 July 2012 in Differentiation
Verified
Journal Article
Closed access
BKBoudewijn Kruithof
Boudewijn Kruithof
SDSjoerd N. Duim
Sjoerd N. Duim
AMAsja T. Moerkamp
Asja T. Moerkamp
MGMarie-José Goumans
Marie-José Goumans

Verified
Journal Article
Open access
PDF file
AWAniek L. van Wijngaarden
Aniek L. van Wijngaarden
BKBoudewijn Kruithof
Boudewijn Kruithof
TVTommaso Vinella
Tommaso Vinella
DBDaniela Q.C.M. Barge-Schaapveld
Daniela Q.C.M. Barge-Schaapveld
Nina Ajmone MarsanNina Ajmone Marsan
Nina Ajmone Marsan
Degenerative mitral valve disease causing mitral valve prolapse is the most common cause of primary mitral regurgitation, with two distinct phenotypes generally recognized with some major differences, i.e., fibroelastic deficiency (FED) and Barlow’s disease. The aim of this review was to describe the main histological, clinical and echocardiographic features of patients with FED and Barlow’s disease, highlighting the differences in diagnosis, risk stratification and patient management, but also the still significant gaps in understanding the exact pathophysiology of these two phenotypes.

1 January 2016 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
SDSjoerd N. Duim
Sjoerd N. Duim
ASAnke Smits
Anke Smits
BKBoudewijn Kruithof
Boudewijn Kruithof
MGMarie-José Goumans
Marie-José Goumans

8 September 2019 in Cardiovascular Research
Verified
Journal Article
Open access
BKBoudewijn Kruithof
Boudewijn Kruithof
LPLaura Paardekooper
Laura Paardekooper
YHYasmine L Hiemstra
Yasmine L Hiemstra
MGMarie-José Goumans
Marie-José Goumans
Meindert PalmenMeindert Palmen
Meindert Palmen
NMNina Ajmone Marsan
Nina Ajmone Marsan
Aims: In mitral valve prolapse (MVP), leaflet thickening has recently been suggested to be due, in addition to a myxomatous degeneration, to the presence of a superimposed tissue (SIT), defined as an additional fibrous layer on top of the original leaflet. The mechanisms of SIT formation are currently unknown. We hypothesized that SIT formation would result from excessive leaflet stress and we used a unique ex vivo model to assess the correlation between leaflet remodelling and the type and location of mechanical stress and to elucidate the mechanisms underlying SIT formation. Methods and results: Human diseased mitral valves (MVs; n = 21) were histologically analysed for SIT formation and original leaflet thickening. The SIT comprised of various compositions of extracellular matrix and could reach more than 50% of total leaflet thickness. Original leaflet and SIT thickness did not show significant correlation (r = −0.27, P = 0.23), suggesting different regulatory mechanisms. To study the role of the mechanical environment on MV remodelling, mouse MV were cultured in their natural position in the heart and subjected to various haemodynamic conditions representing specific phases of the cardiac cycle and the MVP configuration. SIT formation was induced in the ex vivo model, mostly present on the atrial side, and clearly dependent on the duration, type, and extent of mechanical stress. Specific stainings and lineage tracing experiments showed that SIT comprises of macrophages and myofibroblasts and is associated with the activation of the transforming growth factor-beta and bone morphogenetic protein signalling pathways. Migration of valvular interstitial cells and macrophages through breakages of the endothelial cell lining contributed to SIT formation. Conclusions: Mechanical stresses induce specific cellular and molecular changes in the MV that result in SIT formation. These observations provide the first insights in the mechanism of SIT formation and represent an initial step to identify potential novel and early treatment for MVP.

17 January 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
JZJing Zhang
Jing Zhang
MDMaarten van Dinther
Maarten van Dinther
MTMidory Thorikay
Midory Thorikay
BGBabak Mousavi Gourabi
Babak Mousavi Gourabi
BKBoudewijn Kruithof
Boudewijn Kruithof
PDPeter Ten Dijke
Peter Ten Dijke
Ubiquitin-specific protease (USP)19 is a deubiquitinating enzyme that regulates the stability and function of multiple proteins, thereby controlling various biological responses. The alternative splicing of USP19 results in the expression of two major encoded variants that are localized to the endoplasmic reticulum (ER) (USP19-ER) and cytoplasm (USP19-CY). The importance of alternative splicing for the function of USP19 remains unclear. Here, we demonstrated that USP19-CY promotes TGF-β signaling by directly interacting with TGF-β type I receptor (TβRI) and protecting it from degradation at the plasma membrane. In contrast, USP19-ER binds to and sequesters TβRI in the ER. By decreasing cell surface TβRI levels, USP19-ER inhibits TGF-β/SMAD signaling in a deubiquitination-independent manner. Moreover, USP19-ER inhibits TGF-β-induced epithelial–mesenchymal transition (EMT), whereas USP19-CY enhances EMT, as well as the migration and extravasation of breast cancer cells. Furthermore, USP19-CY expression is correlated with poor prognosis and is higher in breast cancer tissues than in adjacent normal tissues. Notably, the splicing modulator herboxidiene inhibits USP19-CY, increases USP19-ER expression and suppresses breast cancer cell migration. Targeting USP19 splicing or its deubiquitinating activity may have potential therapeutic effects on breast cancer.